股票代码：002728 股票简称：特一药业 公告编号：2025-019 特一药业集团股份有限公司 特一药业集团股份有限公司（以下简称"公司"）第五届董事会第三十次会议于 2025 年 4 月 25 日 9:00 在公司会议室采用现场及通讯方式召开，会议通知于 2025 年 4 月 15 日以邮件或书面等形式发出，本次会议应出席董事 6 名，实际出席 6 名（其中许 松青、卢北京、赵晓波、赖瀚琪以通讯表决方式出席会议）。公司监事及高级管理人员 列席了本次会议。会议的召集、召开符合《公司法》和《公司章程》的相关规定。 二、董事会会议审议情况 会议由董事长许丹青主持，全体董事经过审议，以现场及通讯方式进行表决，通过 了如下决议： 1、审议通过《2024 年度董事会工作报告》 详见同日刊登在巨潮资讯网上的《2024 年度董事会工作报告》。 （表决结果：同意票 6 票，反对票 0 票，弃权票 0 票。） 本议案尚需提交股东会审议。 2、审议通过《2024 年度总经理工作报告》 （表决结果：同意票 6 票，反对票 0 票，弃权票 0 票。） 关于第五届董事会第三十次会议决议的公告 本公司及董事会全体成员保证信息披露的内容 ...

股票代码：002728 股票简称：特一药业 公告编号：2025-021 特一药业集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、审议程序 特一药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第五届 董事会第三十次会议和第五届监事会第二十六次会议，审议通过了《关于 2024 年度利 润分配预案的议案》，本议案尚需提交公司 2024 年年度股东会审议。 二、利润分配预案的基本情况 （一）本次利润分配预案的基本内容 1、分配基准：2024 年度 额为 118,879,262.34 元，占本年度净利润的 580.04%。 （二）在利润分配预案公告后至实施前，如公司享有利润分配权的总股本由于股权 激励行权、股份回购等原因发生变化的，按照分配比例不变的原则，相应调整分红总额， 具体金额以实际派发情况为准（注：公司通过回购专户持有的本公司股份，不享有参与 利润分配的权利）。 三、现金分红预案的具体情况 | 项目 | 2024 年度 | 2023 年度 | 2022 年度 | | -- ...

Financial Performance - The company's operating revenue for 2024 was ¥687,785,167, representing a decrease of 35.55% compared to ¥1,067,212,110 in 2023[19] - The net profit attributable to shareholders for 2024 was ¥20,495,003.39, a significant decline of 91.90% from ¥253,175,789.62 in the previous year[19] - The net cash flow from operating activities was negative at -¥22,549,753.56, down 111.36% from ¥198,557,705 in 2023[19] - Basic earnings per share for 2024 dropped to ¥0.04, a decrease of 92.73% compared to ¥0.77 in 2023[19] - Total assets at the end of 2024 were ¥2,400,875,824, reflecting a decrease of 4.45% from ¥2,512,636,670 in 2023[20] - The net assets attributable to shareholders decreased by 12.22% to ¥1,764,933,238 at the end of 2024 from ¥2,010,681,910 in 2023[20] - The company reported a weighted average return on equity of 1.10% for 2024, down from 16.57% in 2023, indicating a significant decline in profitability[19] Dividend Distribution - The company plans to distribute a cash dividend of ¥0.5 per 10 shares to all shareholders, with no stock dividends issued[3] - The proposed cash dividend distribution is RMB 0.50 per 10 shares (including tax), with a total cash dividend amounting to RMB 25,029,009.70 (including tax)[169] - The total distributable profit at the end of the reporting period is RMB 353,494,039.54, with the cash dividend amount representing 100% of the total profit distribution[166] - The company has not proposed any stock dividends or capital reserve transfers in the current profit distribution plan[168] Market Position and Strategy - The company has a strong market position in traditional Chinese medicine, with its core product, the cough remedy, ranked among the top ten brands in its category[33] - Recent government policies are expected to provide significant opportunities for the development of traditional Chinese medicine, enhancing the industry's growth potential[34] - The company is focusing on enhancing product quality and marketing strategies to improve its competitive edge in the market[33] - The company is actively exploring innovative development paths to strengthen its competitiveness in the innovative drug sector[30] - The company aims to enhance brand awareness and reputation while reducing shipments of Cough Relief Tablets, resulting in higher sales expenses[43] Research and Development - The company holds 35 invention patents, 23 design patents, and 8 utility model patents as of the end of the reporting period[41] - The company is advancing several R&D projects aimed at improving product competitiveness and market share, including consistency evaluations for various pharmaceutical products[65] - The total R&D investment amounted to 47,347,279.88 in 2024, representing 6.88% of operating revenue, an increase of 1.90% from 2023[67] - The company is focusing on the innovation and development of traditional Chinese medicine, aligning with national policies to promote the industry, and plans to leverage its existing product lines for market expansion[104] Operational Challenges - The company has indicated potential risks in its future operations, which investors should be aware of[3] - The company has not made any changes to its main business since its listing[19] - The company has seen a significant increase in shareholding for Xu Songqing, with a total of 40,572,000 shares after the rights distribution[133] - The lengthy and costly drug development process presents risks, but the company is committed to improving its R&D capabilities and collaborating with external research institutions to advance high-quality generic drug projects[119] Environmental Compliance - The company holds valid pollution discharge permits for its subsidiaries, with expiration dates ranging from 2025 to 2027[190] - The company adheres to multiple environmental protection laws and industry standards, including the "Water Pollutants Discharge Standards for Traditional Chinese Medicine"[189] - The company has established a comprehensive internal control system to prevent financial misstatements and fraud[184] - The company has developed an environmental self-monitoring plan, conducting daily monitoring of pollutant emissions and engaging third-party testing agencies for regular assessments[200] Governance and Management - The company has established a robust governance structure, complying with relevant laws and regulations[126] - The company actively protects the rights of minority shareholders during shareholder meetings[126] - The company has a dedicated investor relations management system to ensure transparent communication with investors[127] - The company has a total of 901,600 shares held by the financial director after a stock option exercise[133] Employee and Talent Management - The company has implemented a training plan to foster talent development aligned with its strategic goals[157] - The company has a total of 1,341 employees, with 705 in the parent company and 636 in major subsidiaries[155] - The professional composition includes 722 production personnel, 203 sales personnel, and 290 technical personnel[155] - The management team includes experienced professionals with backgrounds in pharmaceutical technology and management[145]

Financial Performance - The company's revenue for Q1 2025 reached ¥295,133,348.45, representing a 79.29% increase compared to ¥164,611,744.46 in the same period last year[5] - Net profit attributable to shareholders was ¥31,567,273.65, a significant increase of 244.82% from ¥9,154,620.96 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥31,706,892.60, reflecting a 255.28% increase from ¥8,924,581.10 in the previous year[5] - Basic earnings per share increased to ¥0.06, a 200.00% rise from ¥0.03 in the previous year[5] - Operating profit for the current period was ¥39,868,269.15, compared to ¥11,312,896.62 in the previous period, reflecting an increase of approximately 252.5%[17] - The net profit for the current period is 31,567,273.65, compared to 9,154,620.96 in the previous period, representing a significant increase[18] Cash Flow - Operating cash flow net amount improved to ¥89,383,755.80, a 327.00% increase from -¥39,376,492.11 in the same period last year[5] - Cash inflow from operating activities totaled 335,732,874.13, compared to 167,275,775.68 in the previous period, indicating a growth of 100.5%[20] - The net cash flow from operating activities is 89,383,755.80, a turnaround from a negative cash flow of -39,376,492.11 in the previous period[20] - Cash outflow from investing activities was 159,330,790.44, compared to 66,834,461.53 in the previous period, reflecting an increase of 138.2%[21] - The net cash flow from investing activities is -68,944,379.48, worsening from -46,812,491.92 in the previous period[21] - Cash inflow from financing activities was 274,580,687.52, down from 292,915,169.80 in the previous period[22] - The net cash flow from financing activities is -143,692,283.28, compared to -78,472,431.97 in the previous period, indicating a decline[22] - The ending cash and cash equivalents balance is 179,708,816.53, down from 382,154,235.62 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,221,913,600.05, a decrease of 7.45% from ¥2,400,875,824.19 at the end of the previous year[5] - Current assets decreased from ¥950,947,063.46 to ¥777,616,074.33, a reduction of approximately 18.2%[16] - Cash and cash equivalents dropped from ¥457,414,315.11 to ¥230,161,408.15, a decrease of about 49.7%[16] - Short-term borrowings decreased significantly from ¥516,093,372.63 to ¥260,000,000.00, a reduction of approximately 49.6%[16] - The total liabilities decreased from ¥635,942,585.62 to ¥423,433,632.10, a decline of about 33.4%[16] - The company's retained earnings increased from ¥353,494,039.54 to ¥385,061,313.19, an increase of approximately 8.9%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 63,146[10] - The largest shareholder, Xu Danqing, holds 27.31% of the shares, totaling 139,973,400 shares[10] - The top ten shareholders include both individual and institutional investors, with significant holdings by Xu family members[11] - There are no preferred shareholders reported in the current period[12] Marketing and Investment - The company reported a significant increase in sales expenses, which rose by 238.02% to ¥85,855,783.63 due to increased investment in new media advertising[9] - Brand building investment amounted to 106 million RMB during the reporting period[12] - The company is undergoing marketing organizational changes and brand marketing construction since 2024, with initial positive results[12] - The company emphasizes risk prevention and financial strategy optimization amid ongoing marketing reforms[12] - The company maintains a focus on long-term development while adapting to market changes[12] - The company warns investors to be aware of investment risks due to ongoing marketing reforms[12] Research and Development - Research and development expenses were ¥9,512,915.33, down from ¥11,100,583.43, indicating a decrease of about 13.5%[17] Other Information - The company has not undergone an audit for the first quarter report[23]

特一药业此番回购计划与高效行动，充分彰显其稳定市场的坚定决心。未来，特一药业将依托自身实力 与坚定信心，在复杂市场环境中稳步前行，持续提升公司价值，为投资者带来更丰厚回报，助力行业稳 定发展。 正如此次回购公告传递出的信号，特一药业这一系列举措并非单纯应对短期市场波动，而是基于长期价 值的主动布局。通过回购可以稳定市场预期、强化激励机制、凝聚核心团队等竞争壁垒，形成"信心传 递-机制保障-价值成长"的良性闭环。在全球产业链重构与科技革命加速推进的大背景下，这种兼具战 略眼光与强大执行力的基本面优势，正是特一药业穿越市场周期、持续创造价值的核心动力之一。 对于特一药业的回购股票行动，市场人士普遍认为，这是企业在复杂环境中主动担当的有力体现。不管 市场怎么变化，上市公司均需通过透明沟通与务实行动，向市场传递价值信号。随着政策工具精准发 力，激励机制不断完善，未来将有更多上市公司积极行动起来，在为投资者持续创造长期价值的同时， 携手营造规范透明、健康向上的市场生态。 关键词阅读：特一药业 在全球经济受美国"关税霸权"冲击，资本市场波动愈发剧烈的当下，特一药业（002728）(002728.SZ)积 极响应金融界对上 ...

股票代码：002728 股票简称：特一药业 公告编号：2025-018 特一药业集团股份有限公司 关于股份回购进展情况的公告 本次回购股份资金来源为公司自有资金，回购价格未超过回购方案中拟定的价格上 限 12.96 元/股（含）。本次回购符合公司回购股份方案及相关法律、法规的要求。 二、其他说明 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托时段均 符合《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回 购股份》及公司回购股份方案的相关规定。具体情况如下： 1、公司未在下列期间内回购股票： 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2024 年 6 月 11 日召开第五届董事会第二十三次会议，审议通过了《关于回购公司股份方案的议案》， 同意公司以自有资金采取集中竞价交易方式回购公司股份，用于股权激励或员工持股计 划，本次公司回购股份的种类为公司已发行的人民币普通股（A 股）股票，回购股份的 资金总额不低于人民币 7,000 万元（含）且不超过人民币 ...

股票代码：002728 股票简称：特一药业 公告编号：2025-017 特一药业集团股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2024 年 6 月 11 日召开第五届董事会第二十三次会议，审议通过了《关于回购公司股份方案的议案》， 同意公司以自有资金采取集中竞价交易方式回购公司股份，用于股权激励或员工持股计 划，本次公司回购股份的种类为公司已发行的人民币普通股（A 股）股票，回购股份的 资金总额不低于人民币 7,000 万元（含）且不超过人民币 12,000 万元（含），回购股 份的价格不超过人民币 12.96 元/股（含）。本次回购期限自公司董事会审议通过本次 回购股份方案之日起 12 个月内。具体内容详见公司刊载于巨潮资讯网的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号— —回购股份》的相关规定，公司应当在每个月的前三个交易日内披露截至上月末的回购 进展情况。现将公司回购公司股份的进展情况公告如下： 购股份 ...

股票代码：002728 股票简称：特一药业 公告编号：2025-016 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2024 年 5 月 10 日召开第五届董事会第二十二次会议，审议通过了《关于使用可转债部分闲置募集资 金暂时补充流动资金的议案》，为了有效提高募集资金的使用效率，减少财务费用，降 低运营成本，维护公司和股东利益，在确保公司可转换公司债券募集资金投资项目按进 度实施的前提下，同意公司使用不超过人民币 6,000 万元可转债闲置募集资金暂时补充 流动资金，董事会审议通过后，自首次办理暂时补充流动资金之日起，不超过 12 个月， 到期后归还至募集资金专用账户。具体内容详见公司于 2024 年 5 月 11 日刊登于法定媒 体及巨潮资讯网（http://www.cninfo.com.cn/）上的《关于使用可转债部分闲置募集 资金暂时补充流动资金的公告》（公告编号：2024-039）。 在使用可转债部分闲置募集资金暂时补充流动资金期间，公司通过合理安排，资金 运作良好。2025 年 4 月 1 日，公司将上述用于暂时补充流动资金的募集资金人民币 800 万元提前归还至募集资金专用账户， ...

Core Viewpoint - The company is undergoing significant marketing transformation and organizational restructuring, which is expected to lead to long-term benefits despite short-term declines in performance [3][4]. Group 1: Share Buyback and Financial Performance - As of February 28, 2025, the company has repurchased 12,729,618 shares through the Shenzhen Stock Exchange, reflecting a commitment to enhancing shareholder value [2]. - The company forecasts a net profit of 20-25 million yuan for 2024, representing a year-on-year decline of 90.13%-92.10%, with a non-recurring net profit of 16.7-21.7 million yuan, down 91.29%-93.29% [2]. Group 2: Marketing and Sales Strategy - The company is focusing on a "foundation-building, long-term benefit" strategy, establishing a self-operated organizational structure to improve sales channel integration and pharmacy sales [3]. - Sales of the core product, cough tablets, have seen a significant decline, with 2024 sales expected to be 230 million tablets compared to over 1 billion tablets in 2023, primarily due to reduced shipments [3]. - The company has increased brand promotion efforts, particularly in new media, leading to higher sales expense ratios [3]. Group 3: Product Outlook - The cough tablets are expected to recover in sales due to their effectiveness in treating chronic bronchitis and the aging population, with a target of reaching 10 million boxes in sales over the next 3-5 years [4]. - As of January 2025, sales data indicates a recovery in cough tablet sales in pharmacies, although not yet reaching the levels of the same period in 2023 [4]. Group 4: Share Buyback Purpose - The share buyback program, approved in June 2024, aims to use repurchased shares for employee stock ownership plans, with a total funding of 70-120 million yuan and a maximum repurchase price of 12.96 yuan per share [5]. - As of February 28, 2025, the company has spent approximately 93.94 million yuan on share repurchases, indicating confidence in future growth and potential to enhance employee motivation [5].

Investment Rating - The report maintains a rating of "Accumulate" for the company [5] Core Views - The company is undergoing a marketing transformation aimed at long-term benefits, which has led to a significant decline in sales of its core product, the cough lozenge [1][2] - Despite the short-term challenges, the company is expected to benefit from improved market management and brand strength in the long run [1] - The cough lozenge has shown strong sales potential, with a target of reaching 100 million boxes in sales over the next 3-5 years [2] - The company has initiated a share buyback program to boost employee morale and demonstrate confidence in future growth [2] Summary by Sections Company Performance - As of February 28, 2025, the company has repurchased 12,729,618 shares, reflecting a total expenditure of approximately 93.94 million yuan [1][2] - The 2024 annual performance forecast indicates a net profit of 20-25 million yuan, a year-on-year decline of 90.13%-92.10% [1] Sales and Marketing Strategy - The company has restructured its marketing organization to focus on self-operated sales channels, which has temporarily reduced the sales of the cough lozenge [1] - The sales volume of the cough lozenge reached over 1 billion pieces in 2023, but is projected to drop to 230 million pieces in 2024 [1][2] Financial Projections - The profit forecast for 2024-2026 has been adjusted to 0.23 billion, 1.46 billion, and 2.32 billion yuan respectively, with significant downward revisions of 92%, 60%, and 48% [3] - The current price-to-earnings (P/E) ratio is projected to be 183, 28, and 18 for the years 2024, 2025, and 2026 respectively [3] Market Outlook - The company aims to achieve a recovery in sales volume for the cough lozenge by 2025-2026, supported by marketing reforms and increased brand investment [2][3] - The report emphasizes the long-term growth potential of the company due to its unique product offerings and strong market position [3]